LENOIR, N.C.--(BUSINESS WIRE)--GREER®, a leading developer and provider of allergy immunotherapy products and services, announced the initial results from its investigational pivotal Phase III clinical trial that studied the effectiveness of sublingual immunotherapy (SLIT) as a treatment for adults with allergic rhinoconjunctivitis caused by short ragweed pollen. The primary objective of the randomized, multi-centered, double-blind, placebo controlled, parallel group trial was to evaluate the efficacy and safety of GREER Sublingual (standardized short ragweed extract) Allergy Immunotherapy Liquid (SAIL)™. The trial was conducted prior to and during the ragweed pollen season of 2011. The intent-to-treat (ITT) analysis met its primary endpoint with a 43% reduction in the total combined (symptom + medication use) score relative to placebo (p=0.0032).
